LLY Eli Lilly and Company
Company Analysis
Latest News
Eli Lilly Widens Lead in Obesity Market as Wall Street Bets on Oral GLP-1 Pipeline
JPMorgan, Deutsche Bank, and RBC Capital reiterated their confidence in Eli Lilly’s leadership within the expanding obesity treatment market. The investment...
Lilly’s Oral Orforglipron Outperforms Novo’s Semaglutide in Landmark Head-to-Head Trial
Eli Lilly’s experimental once-daily oral drug, orforglipron, demonstrated superior efficacy over Novo Nordisk’s oral semaglutide in a Phase 3 head-to-head...
Eli Lilly Shares Slide as Novo Nordisk Signals 50% Price Cuts for GLP-1 Rivals
Eli Lilly (LLY) shares declined in premarket trading following a pricing announcement from primary rival Novo Nordisk. Novo Nordisk plans to reduce prices for...
Eli Lilly Stock Jumps on Zepbound KwikPen Approval as Rival Novo Nordisk Tumbles 16%
Eli Lilly and Company received U.S. FDA approval for the Zepbound KwikPen, a multi-dose injector for its weight-loss medication. This new device delivers four...
Eli Lilly Shares Surge as Novo Nordisk Weight-Loss Trial Fails
Eli Lilly (LLY) shares surged 4.84% to close at $1058.39 following a clinical setback for competitor Novo Nordisk and the official launch of the Zepbound...
🟢 LLY is trading 3.16% up today after Mounjaro outperforms Novo Nordisk's CagriSema in head-to-head trial
LLY is trading at $1041.44 (+3.16%) after its obesity drug Mounjaro outperformed Novo Nordisk's CagriSema in a head-to-head Phase 3 trial. • The study...
🟢 LLY is trading 2.72% up today as Mounjaro outperforms Novo Nordisk's CagriSema in head-to-head study
LLY is trading at $1037.00 (+2.72%) in pre-market action after Eli Lilly's Mounjaro outperformed Novo Nordisk's rival drug CagriSema in a head-to-head clinical...
Barclays Initiates Overweight Coverage on Eli Lilly with $1,350 Target
Barclays initiated coverage on Eli Lilly (LLY) with an Overweight rating and a $1,350 price target, reflecting continued bullish sentiment following several...
Eli Lilly’s Omvoh Maintains 92% Remission in Crohn’s Disease Through Three Years
Eli Lilly released three-year Phase 3 data for its Crohn's disease treatment, Omvoh (mirikizumab). The study found that 92.4% of patients who responded to...
Eli Lilly Combination Therapy Achieves Superior Skin Clearance and Weight Loss in Phase 3b Psoriasis Trial
Eli Lilly and Company reported positive topline results from the TOGETHER-PsO Phase 3b clinical trial. The study evaluated Zepbound (tirzepatide) combined with...
Eli Lilly to Invest $1 Billion in India Hub to Scale Global Supply and Launch New Drugs
Eli Lilly and Company will invest $1 billion to establish India as a central hub for its global supply chain. The pharmaceutical giant will utilize local...
Eli Lilly’s Retevmo Becomes First RET Inhibitor to Succeed in Phase 3 Early-Stage Lung Cancer Trial
Eli Lilly and Company reported positive topline results from its Phase 3 LIBRETTO-432 clinical trial evaluating Retevmo (selpercatinib). The study tested the...
Eli Lilly Stockpiles $1.5 Billion of Experimental Weight-Loss Drug Ahead of FDA Ruling
Eli Lilly (LLY) has built a $1.5 billion inventory of its experimental oral obesity drug, orforglipron, ahead of an expected 2026 FDA decision to aggressively...
Eli Lilly in after-hours trading at $1042.00 amid analyst upgrades and stockpile news
Eli Lilly shares rose 2.34% to close at $1038.96 after Freedom Capital Markets upgraded the stock to Buy with a $1200 price target. The upgrade highlights the...
🟢 LLY is trading 3% up today following Freedom Capital upgrade and Orna acquisition
LLY is trading at $1045.74 (+3.01%) today following a Freedom Capital upgrade to Buy and the company's $2.4B acquisition of Orna Therapeutics. • Freedom...
Eli Lilly Secures China Approval for Mirikizumab, Tapping World’s Second-Largest Pharma Market
Eli Lilly and Company received approval from Chinese regulators on Wednesday for its drug, mirikizumab. The authorization covers the treatment of adults with...
Eli Lilly Upgraded to Buy Following $2.4 Billion Acquisition of Orna Therapeutics
Freedom Capital analyst Ilya Zubkov has upgraded Eli Lilly to Buy from Hold with a price target of $1,200, citing strong growth momentum. The upgrade follows a...
Eli Lilly Diversifies Beyond GLP-1s with $10.9 Billion in New Biotech Deals
Eli Lilly aggressively expanded its clinical pipeline through two major deals totaling nearly $11 billion, focusing on circular RNA and immunology. Despite...
Eli Lilly Acquires Orna Therapeutics for $2.4 Billion to Advance Circular RNA Pipeline
Eli Lilly announced it is acquiring biotechnology firm Orna Therapeutics for $2.4 billion in cash, securing a key technology platform to strengthen its...
🟢 LLY is trading 3.4% up today on $2.4B Orna Therapeutics acquisition
LLY is trading at $1,094.23 (+3.4%) following Eli Lilly's announcement of a definitive agreement to acquire Orna Therapeutics for up to $2.4 billion. • The...